Status:
TERMINATED
Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
AIDS Related Lymphoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Most treatment procedures in AIDS-related lymphomas disclose a relatively poor outcome for patients with low response rates, high number of relapses and AIDS events. The addition of rituximab to the s...
Detailed Description
HIV infection is associated with a high incidence of AIDS-related lymphomas (ARL). Since the use of highly active antiretroviral therapy (HAART), the incidence of AIDS-defining illnesses has decreased...
Eligibility Criteria
Inclusion
- HIV positive with a high grade Ann Arbor stage I to IV untreated non-Hodgkin's lymphoma of B-cell origin confirmed by biopsy. The following histologies are eligible: \*Burkitt's lymphoma, \*diffuse large B-cell with standard histological diagnosis, \*Burkitt-like and high grade large cell immunoblastic lymphoma with immunophenotyping CD20 positive
- Good and intermediate prognostic group (no more than one of the following prognostic factors: \*CD4 below 100/µl, \*history of opportunistic infection, \*Karnofsky index below 60 percent or ECOG over 2)
- Written inform consent to participate
Exclusion
- Active viral hepatitis
- Pregnancy
Key Trial Info
Start Date :
January 1 1999
Trial Type :
INTERVENTIONAL
End Date :
October 1 2003
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00126243
Start Date
January 1 1999
End Date
October 1 2003
Last Update
August 17 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Medecine Interne Hopital Antoine Beclere
Clamart, France, 92140